6-(2-bromoethyl)-benzimidazolone | 122884-00-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 6-(2-bromoethyl)-benzimidazolone
• 英文别名: 5-(2-bromoethyl)benzimidazol-2-one
• CAS: 122884-00-8
• 化学式: C₉H₇BrN₂O
• 分子量: 239.071
• InChiKey: PVABLRWKKBXIDZ-UHFFFAOYSA-N

物化性质

• 沸点：
  330.0±44.0 °C(Predicted)
• 密度：
  1.71±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  41.8
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  6-(2-bromoethyl)-benzimidazolone 、 1-(1-萘基)对二氮已环 、 4-甲基-2-戊酮 在 sodium iodide 盐酸 、 N2 、 sodium carbonate 作用下， 以 四氢呋喃 为溶剂， 以14%的产率得到6-(2-(4-(1-naphthyl)piperazinyl)ethyl)-benzimidazolone
  参考文献：
  名称：

  Aryl piperazinyl-(C.sub.2 or C.sub.4) alkylene heterocyclic compounds

  摘要：

  芳基哌嗪基乙基（或丁基）杂环化合物及其药用可接受的酸盐是神经阻滞剂。它们在治疗精神病性障碍方面很有用。

  公开号：

  US04831031A1

文献信息

• Method of treating tourette's syndrome and obsessive compulsive disorder
  申请人：Pfizer Inc.

  公开号：US06127373A1

  公开（公告）日：2000-10-03

  A method for treating Tourette's syndrome, obsessive compulsive disorder, chronic motor or vocal tic disorder in a mammal, including a human, comprising administering to said mammal an effective amount of a compound of the formula ##STR1## or a pharmaceutically acceptable acid addition salt thereof, wherein n, X, Y and Ar are as defined above.

  在哺乳动物，包括人类中，治疗抽动症、强迫症、慢性运动或发声抽动障碍的方法，包括向该哺乳动物施用公式##STR1##中的化合物或其药用可接受的酸盐的有效量，其中n、X、Y和Ar如上所定义。
• Aryl piperazinyl-(C.sub.2 or C.sub.4) alkylene heterocyclic compounds
  申请人：Pfizer Inc.

  公开号：US04831031A1

  公开（公告）日：1989-05-16

  Arylpiperazinyl-ethyl(or butyl)-heterocyclic compounds and their pharmaceutically acceptable acid addition salts are neuroleptic agents. They are useful in the treatment of psychotic disorders.

  芳基哌嗪基乙基（或丁基）杂环化合物及其药用可接受的酸盐是神经阻滞剂。它们在治疗精神病性障碍方面很有用。
• METHOD OF TREATING GLAUCOMA AND ISCHEMIC RETINOPATHY
  申请人：——

  公开号：US20020004504A1

  公开（公告）日：2002-01-10

  A method for treating glaucoma and ischemic retinopathy in a mammal, comprising administering to said mammal a therapeutically effective amount of a compound of the formula 1 or a pharmaceutically acceptable acid addition salt thereof, wherein n, X, Y and Ar are as defined in the specification.

  在哺乳动物中治疗青光眼和缺血性视网膜病的方法，包括向所述哺乳动物施用公式1的化合物或其药学上可接受的酸盐的治疗有效量，其中n、X、Y和Ar如规范中定义。
• Anxiety treatments with ziprasidone
  申请人：Romano Joseph Steven

  公开号：US20050004138A1

  公开（公告）日：2005-01-06

  The present invention, in one aspect, relates to a method of using piperazinyl-heterocyclic compounds of the formula I, as defined below, for treating, in a mammal, including a human, situational anxiety, for example, anxiety experienced prior to medical procedures (e.g., surgery), public speaking, anxiety associated with swimming or water, anxiety associated with travel (e.g., air travel), or anxiety associated with specific phobias (snakes, spider, rats, sight of blood), comprising administering a pharmaceutically effective amount of a compound of formula I to the mammal. In another aspect, the present invention is directed to a method of using piperazinyl-heterocyclic compounds of the formula I, as defined below, for treating, in a mammal, including a human, treatment-resistant anxiety, which method comprises administering a pharmaceutically effective amount of a compound of formula I to the mammal. The compounds of formula I are defined as follows: or a pharmaceutically acceptable acid addition salt thereof, wherein Ar, n, X, and Y are as defined.

  本发明在某些方面涉及使用以下式子定义的哌嗪基-杂环化合物的方法，用于治疗哺乳动物，包括人类的情境焦虑，例如在医疗程序（例如手术）、公共演讲、与游泳或水有关的焦虑、与旅行（例如空中旅行）有关的焦虑或与特定恐惧症（蛇、蜘蛛、老鼠、血液视觉）有关的焦虑，包括向哺乳动物投与化学有效量的式子I的化合物。在另一个方面，本发明涉及使用以下式子定义的哌嗪基-杂环化合物的方法，用于治疗哺乳动物，包括人类的难治性焦虑，其中该方法包括向哺乳动物投与化学有效量的式子I的化合物。式子I的化合物定义如下：或其药学上可接受的酸盐，其中Ar、n、X和Y如上定义。
• Treatment of psychotic and depressive disorders
  申请人：Romano Joseph Steven

  公开号：US20050004137A1

  公开（公告）日：2005-01-06

  The present invention relates to a method for treating a psychiatric conditions and disorders selected from delusional disorder, psychosis associated with dementia, such as psychosis associated with Alzheimer's disease, psychosis associated with an organic brain syndrome (e.g. stroke, or a viral infection such as an HIV infection), and drug-induced psychosis in mammals, including humans, comprising administering an effective amount of a compound of the formula I: or a pharmaceutically acceptable acid addition salt thereof, wherein Ar, n, X, and Y are as defined The present invention also relates to a method for treating a depressive disorder selected from melancholic depression, severe depression, psychotic depression, and treatment-resistant depression in mammals, including humans, comprising administering a compound of formula I, or a pharmaceutically acceptable acid addition salt of such compound.

  本发明涉及一种治疗精神病症和障碍的方法，所述症状包括妄想症、与痴呆症相关的精神病，例如与阿尔茨海默病相关的精神病、与器质性脑病综合症相关的精神病（例如中风或病毒感染，如HIV感染）以及哺乳动物，包括人类中的药物诱导性精神病，其包括向患者投予化合物I式的有效量，或其药学上可接受的酸盐加合物，其中Ar、n、X和Y如定义所述。本发明还涉及一种治疗哺乳动物，包括人类中的忧郁症的方法，所述忧郁症包括忧郁症、重度抑郁症、精神病性抑郁症和难治性抑郁症，其包括向患者投予化合物I式或其药学上可接受的酸盐加合物。